Our placement rate improved during the quarter which is encouraging given the low prevalence rate and customer interest in discussing flu this time of the year. Other assays for hCG strep and RSV are planned to follow shortly and we would expect by the first quarter of 2013 to have a menu of four tests in the United States and six tests in Europe with still others to follow throughout the year.The other key near-term initiative is AmpliVue our handheld disposable molecular platform that combines isothermal amplification with traditional lateral flow detection. We received CE mark for our C. difficile product in March, completed U.S. clinical trials in the second quarter and have been building inventor for our European product launch in the fall. And then anticipated launch here in the U.S. before the end of the year. We expect assays for MRSA for blood culture confirmation, (inaudible) strep and is to follow shortly.
Quidel's CEO Discusses Q2 2012 Results - Earnings Call Transcript
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts